Related Experiment Video
Updated: Jul 2, 2026
08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
Combination vasodilator therapy for severe chronic congestive heart failure
Annals of Internal Medicine
|October 1, 1976
Summary
For severe congestive heart failure, oral minoxidil and hydralazine effectively reduced vascular resistance and improved cardiac output, offering new treatment options for intractable cases.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Severe, chronic congestive heart failure (CHF) often presents challenges with conventional therapies.
- Patients may become refractory to standard treatments, including nitrates and even nitroprusside.
Observation:
- A case study explored the efficacy of oral minoxidil in a patient with severe, intractable CHF unresponsive to other treatments.
- The patient was dependent on nitroprusside prior to minoxidil initiation.
Findings:
- Oral minoxidil significantly decreased systemic vascular resistance and increased cardiac output without adverse hemodynamic effects.
- Combination therapy with sublingual isosorbide dinitrate further improved cardiac output and reduced venous pressures.
- Oral hydralazine demonstrated comparable hemodynamic effects to oral minoxidil.
Implications:
- Minoxidil and hydralazine show potential for chronic impedance reduction in severe heart failure.
- These findings suggest a need for further clinical trials to evaluate vasodilators like minoxidil and hydralazine in intractable CHF.
- Successful weaning from nitroprusside was achieved with oral vasodilators, indicating a potential shift in treatment paradigms.
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...